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LETTER TO THE EDITOR
IgA Antibodies of Cicatricial Pemphigoid Sera Specifically
React with C-Terminus of BP180
To the Editor
It is generally accepted that the majority of bullous pemphigoid (BP)
sera and a considerable number of cicatricial pemphigoid (CP) sera
recognize a hemidesmosomal component BP180 (Labib et al, 1986;
Bernard et al, 1992). CP, however, shows different clinical features
from BP. Usually, CP has a predominant involvement of oral and
ocular mucous membranes with a tendency of scarring. The different
clinical features betweenBPandCPmight bedue todifferent targeted
epitopes on this antigen, or to a difference of immunoglobulin classes.
Therefore, in this study, we produced three bacterial glutathione-S-
transferase (GST) fusion proteins, named GST-BP-1050, GST-BP-
963, and GST-BP-915, and examined their reactivities with BP and
CP sera.
GST-BP-1050 encodes N-terminal 350 amino acids (542–892);
GST-BP-963 encodes central 321 amino acids (885–1206); and GST-
BP-915 encodes C-terminal 305 amino acids (1227–1532) of BP180
extracellular domain (BP180 ECD) (sequence data referred to Giud-
ice et al, 1992). Put together, these three fusion proteins roughly
cover thewhole BP180ECD. To produce these fusionproteins, three
constructs were generated by inserting three appropriate polymerase
chain reaction-amplified fragments of BP180 cDNA into bacterial
vectors pGEX (Pharmacia, Uppsala, Sweden) (pGEX-3X for GST-
BP-1050, pGEX-2T for GST-BP-963 and GST-BP-915). The
resulted constructs were used to transform E. coli XL-Blue
(Stratagene, La Jolla, CA) or BL21 (Pharmacia, Uppsala, Sweden) (to
reduce the degradation of fusion proteins, BL21 was used for GST-
BP-963 andGST-BP-915). All constructs were sequenced to confirm
the identity and fidelity of subcloning steps. Fusion proteins were
induced by IPTG and purified by glutathione-agarose affinity col-
umns as described previously (Matsumura et al, 1996). The fusion
proteins were of expected sizes as judged by a polyclonal anti-GST
antibody (G-7781, Sigma, St. Louis, MO), i.e., GST-BP-1050 (top
band) being 66 kDa, GST-BP-963 being 62 kDa, GST-BP-915 being
60 kDa. The reactivity of fusion proteins with 20 BP sera, 10 CP sera
and 10 normal control sera, were analyzed by immunoblotting as
described previously (Hashimoto et al, 1990). By direct immuno-
fluorescence, all BP exhibited IgG and all CP showed both IgG and
IgA deposits in BMZ. By indirect immunofluorescence, all BP and
CP sera showed IgG antibodies against the epidermal side of salt-split
skin. Four CP but no BP sera showed IgA anti-BMZ antibodies.
These CP patients had oral and ocular involvement and healed
with scarring.
The representative results were shown in Fig 1. Seventeen (85%),
five (25%), and six (30%) BP sera showed IgG antibodies reactive
with GST-BP-1050, GST-BP-963, and GST-BP-915, respectively.
Three (15%) BP sera reacted with all three fusion proteins. Only one
BP serum reacted exclusively with GST-BP-915. No BP sera showed
IgA antibodies reactive with any fusion proteins. For CP, five (50%),
one (10%), and five (50%) sera showed IgG antibodies reactive with
GST-BP-1050, GST-BP-963, and GST-BP-915, respectively. Four
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(40%) CP sera recognized both GST-BP-1050 and GST-BP-915.
Most interestingly, IgA of four (40%) CP sera reacted with GST-BP-
915 reproducibly.
Thus, our result that 85% BP sera reacted with N-terminus (GST-
BP-1050) of BP180 ECD confirmed the previous studies (Giudice
Figure 1. Multiple fusion proteins were recognized by IgG antibodies
of both BP and CP sera, whereas C-terminal domain was reacted by
IgA antibodies of only CP sera. (a) Immunoblotting for IgG and IgA
antibodies using GST-BP-1050. An arrowhead indicates the positive band of
intact recombinant protein; small bars indicate the degradation products.
(b) Immunoblotting for IgG and IgA antibodies using GST-BP-963. (c)
Immunoblotting for IgG and IgA antibodies using GST-BP-915. In (b) and
(c), arrowheads indicate the positive bands of intact recombinant proteins;
small bars indicate nonspecific bands. The reactivity of three BP sera, which
possessed IgG antibodies reactive with all GST-BP-1050, GST-BP-963, and
GST-BP-915, is shown in lanes 1, 2, and 3 in (a)–(c). The reactivity of three
CP sera, which showed IgG antibodies reactive with both GST-BP-1050
and GST-BP-915, is shown in lanes 4, 5, and 6 in all parts. Among these three
CP sera, one serum showed weak reactivity of IgG antibodies with the central
domain. All the three CP sera are also shown to possess IgA antibodies reactive
with GST-BP-915. Lane 7 in all parts shows the reactivity of a normal
control serum.
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et al, 1993). Next, our results demonstrated that IgG autoantibodies
of a considerable number of BP and CP sera recognized at least N-
terminus (GST-BP-1050) and C-terminus (GST-BP-915) of BP180
ECD, indicating that BP180 ECD contains different epitopes over
its entire sequence. These results were consistent with the previous
study, which showed that 10 of 23 CP sera and six of 14 BP sera
recognized both N-terminus and C-terminus of BP180 ECD (Bald-
ing et al, 1996). Comparison of the reactivities of IgG antibodies with
these fusion proteins between BP and CP did not show an evident
difference in the distribution of epitopes on BP180. In our previous
study, we found that four Japanese CP sera showed both IgG and IgA
antibodies against BP180 (Hashimoto et al, 1997). In this study, we
further demonstrated that IgA autoantibodies of 40% CP sera reacted
with the C-terminal domain of BP180 ECD. Because only one (2%)
of 50 CP sera weakly reacted with a fusion protein containing most
C-terminal 133 amino acids of BP180 (Murakami et al, 1998), it may
be conceivable that the major epitope for IgA antibodies of CP sera
may be present in the amino acids 134–305 from the C-terminal end
of BP180 sequence.
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